Extraction, radioiodination, and in vivo catabolism of equine fibrinogen.

This research investigates the extraction and radiolabeling of equine fibrinogen – a protein involved in blood clotting – and studies its rate of elimination from the plasma of horses.

Method: Extraction and Radioiodination of Equine Fibrinogen

• The researchers isolated equine fibrinogen, a protein crucial for the blood clotting process in horses.
• The isolated fibrinogen was stored at -70°C before undergoing a process called radioiodination. This process entails labeling a compound with radioactive iodine (125I) by using a monochloroiodine reagent. This radioactive iodine isotope has a half-life of 60.2 days and emits gamma radiation at 35 keV.
• Radioiodination efficiencies were observed to be between 49% and 53%, meaning about half of the attempts to label the fibrinogen with iodine resulted in successful labeling.
• The result of the radioiodination process was a labeled fibrinogen product with 98% protein-bound radioactivity, and 91% of the radioactivity could be used in clotting (termed ‘clottable’ radioactivity).

Investigation: In Vivo Catabolism of Radiolabeled Equine Fibrinogen

• The researchers then moved on to examine the rate of elimination (catabolism) of this radio-labeled fibrinogen in living horse bodies (in vivo).
• In six equine in vivo experiments, they found the plasma half-lives of the 125I-labeled fibrinogen to range from 4.1 to 5.2 days. The half-life of a substance is the time it takes for half of it to be metabolized and eliminated from the body.
• These half-life values correspond to an approximated daily plasma elimination rate of 15% for the labeled fibrinogen. This means approximately 15% of the radio-labeled fibrinogen was metabolized and eliminated from the horse’s plasma each day.

This research contributes valuable information to the understanding of equine fibrinogen metabolism, which can be critical for veterinary medicine involving horses.